Kheir Michael M, Ackerman Colin T, Tan Timothy L, Benazzo Andrea, Tischler Eric H, Parvizi Javad
The Rothman Institute at Thomas Jefferson University, Philadelphia, Pennsylvania.
J Arthroplasty. 2017 Jun;32(6):1976-1979. doi: 10.1016/j.arth.2017.01.031. Epub 2017 Jan 26.
Leukocyte esterase (LE) strip test is an accurate marker for diagnosing periprosthetic joint infection (PJI). This study aims to determine if LE is a good predictor of persistent infection and/or subsequent failure in patients undergoing reimplantation.
This single-institution study prospectively recruited and retrospectively analyzed 109 patients who underwent two-stage exchange treatment of PJI, from 2009-2016, and had an LE test performed at time of reimplantation. LE results of "2+" were considered positive. Ninety-five patients had 90-day minimum follow-up to assess treatment failure, defined by Delphi criteria. Eighteen patients were excluded due to blood contamination of LE test, resulting in a final cohort of 77 patients (mean follow-up 1.76 years).
Of the final cohort, 19 patients (24.7%) experienced subsequent failure. At reimplantation, LE test was positive in 22.2% of culture-positive and 4.4% of culture-negative cases. The LE test was negative in all patients who had not failed at latest follow-up, yielding sensitivity, specificity, positive predictive value, negative predictive value, and AUC of 26.3%, 100%, 100%, 87.5%, and 0.632, respectively; in comparison, MSIS criteria respectively yielded 25.0%, 87.3%, 27.6%, 85.8%, and 0.562 (P = .01 for specificity). Kaplan-Meier curves revealed higher failure rate in patients who had a positive LE test at time of reimplantation (P < .001).
There is a dire need for an accurate diagnostic test to determine optimal timing of reimplantation in patients undergoing surgical treatment for PJI. The current study suggests that a positive LE test may be indicative of persistence of infection and results in a higher rate of subsequent failure.
白细胞酯酶(LE)试纸条检测是诊断人工关节周围感染(PJI)的准确标志物。本研究旨在确定LE是否是再植入患者持续性感染和/或后续失败的良好预测指标。
这项单机构研究前瞻性招募并回顾性分析了2009年至2016年期间接受PJI两阶段置换治疗且在再植入时进行LE检测的109例患者。LE结果为“2+”被视为阳性。95例患者进行了至少90天的随访以评估治疗失败情况,治疗失败根据德尔菲标准定义。18例患者因LE检测血液污染被排除,最终队列有77例患者(平均随访1.76年)。
在最终队列中,19例患者(24.7%)出现后续失败。再植入时,培养阳性病例中22.2%的LE检测为阳性,培养阴性病例中4.4%的LE检测为阳性。在最新随访时未失败的所有患者中LE检测均为阴性,敏感性、特异性、阳性预测值、阴性预测值和AUC分别为26.3%、100%、100%、87.5%和0.632;相比之下,肌肉骨骼感染学会(MSIS)标准的相应结果分别为25.0%、87.3%、27.6%、85.8%和0.562(特异性P = 0.01)。Kaplan-Meier曲线显示再植入时LE检测为阳性的患者失败率更高(P < 0.001)。
迫切需要一种准确的诊断测试来确定接受PJI手术治疗患者再植入的最佳时机。当前研究表明LE检测阳性可能表明感染持续存在,并导致更高的后续失败率。